CN105497907A - Instant pidotimod and preparation technology thereof - Google Patents
Instant pidotimod and preparation technology thereof Download PDFInfo
- Publication number
- CN105497907A CN105497907A CN201510985708.1A CN201510985708A CN105497907A CN 105497907 A CN105497907 A CN 105497907A CN 201510985708 A CN201510985708 A CN 201510985708A CN 105497907 A CN105497907 A CN 105497907A
- Authority
- CN
- China
- Prior art keywords
- parts
- pidotimod
- subsequent use
- gelatin
- poured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Fruits And Vegetables (AREA)
Abstract
The invention discloses instant pidotimod comprising raw materials in parts by weight as follows: 4-8 parts of anhydrous citric acid, 2-4 parts of stevioside, 1-3 parts of crosslinked polyvinylpyrrolidone, 2-4 parts of sodium bicarbonate, 3-5 parts of sodium carboxymethyl starch, 6-8 parts of potato starch, 18-20 parts of L-pyroglutamic acid, 15-17 parts of L-4-thiazolidine formate, 8-10 parts of ethyl acetate, 12-14 parts of acetic acid, 6-8 parts of dicyclohexyl carbodiimide, 2-4 parts of L-arginine, 1-3 parts of tetramisol, 4-6 parts of glucomannan and 1-3 parts of gelatin. The instant pidotimod is very high in component dispersion and dissolution speed.
Description
Technical field
The present invention relates to a kind of instant pidotimod and preparation technology thereof.
Background technology
Pidotimod (Pidotimod), researched and developed by Italian PoliindustriachimicaS.P.A company the eighties in 20th century, listing is got permission for clinical in 1993, it is a kind of immunopotentiating agent of synthetic, its similar is in dipeptides, and chemistry is called (4R)-3-[[(2S)-5-oxo-2-pyrrolidinyl] carbonyl]-4-thiazolidinecarboxylic acid; There is mithridatism, irritation, anti-infection property, non-oxidizability, anti-ageing feature of waiting for a long time, can nonspecific immune reaction be promoted, can specific immune response be promoted again; Be mainly used in prevention and therapy child recurrent respiratory infection, urinary system infection, allergic rhinitis and asthma, treat and prevent chronic bronchitis acute attack, upper respiratory tract infection, also can be used for multiple viral infection, malignant tumor and other chronic disease and cause organism immunologic hypofunction.Produce the method for pidotimod and few, at present, in Asia, Europe, all multiple countries listing such as America.Current pidotimod dissolution velocity is on the market slow, and composition dispersion effect is poor.
Summary of the invention
The technical problem to be solved in the present invention is to provide the instant pidotimod and preparation technology thereof that a kind of composition disperses and dissolution velocity is exceedingly fast.
For solving the problem, the present invention adopts following technical scheme:
A kind of instant pidotimod, comprises the raw material of following parts by weight proportioning: anhydrous citric acid 4-8 part, stevioside 2-4 part, crospolyvinylpyrrolidone 1-3 part, sodium bicarbonate 2-4 part, carboxymethyl starch sodium 3-5 part, potato starch 6-8 part, L-Glutimic acid 18-20 part, L-4-thiaproline ester 15-17 part, ethyl acetate 8-10 part, acetic acid 12-14 part, dicyclohexylcarbodiimide 6-8 part, L-arginine 2-4 part, tetramisole 1-3 part, Rhizoma amorphophalli glucomannan 4-6 part and gelatin 1-3 part.
Further, the raw material of following parts by weight proportioning is comprised: anhydrous citric acid 8 parts, stevioside 2 parts, crospolyvinylpyrrolidone 1 part, sodium bicarbonate 2 parts, carboxymethyl starch sodium 3 parts, potato starch 6 parts, L-Glutimic acid 18 parts, L-4-thiaproline ester 15 parts, ethyl acetate 8 parts, acetic acid 12 parts, dicyclohexylcarbodiimide 6 parts, L-arginine 2 parts, tetramisole 1 part, Rhizoma amorphophalli glucomannan 4 parts and 1 part, gelatin.
Further, the raw material of following parts by weight proportioning is comprised: anhydrous citric acid 4 parts, stevioside 4 parts, crospolyvinylpyrrolidone 3 parts, sodium bicarbonate 4 parts, carboxymethyl starch sodium 5 parts, potato starch 8 parts, L-Glutimic acid 20 parts, L-4-thiaproline ester 17 parts, ethyl acetate 10 parts, acetic acid 14 parts, dicyclohexylcarbodiimide 8 parts, L-arginine 4 parts, tetramisole 3 parts, Rhizoma amorphophalli glucomannan 6 parts and 3 parts, gelatin.
Further, the raw material of following parts by weight proportioning is comprised: anhydrous citric acid 6 parts, stevioside 3 parts, crospolyvinylpyrrolidone 2 parts, sodium bicarbonate 3 parts, carboxymethyl starch sodium 4 parts, potato starch 7 parts, L-Glutimic acid 19 parts, L-4-thiaproline ester 16 parts, ethyl acetate 9 parts, acetic acid 13 parts, dicyclohexylcarbodiimide 7 parts, L-arginine 3 parts, tetramisole 2 parts, Rhizoma amorphophalli glucomannan 5 parts and 2 parts, gelatin.
Another technical problem that the present invention will solve is to provide a kind of preparation technology of instant pidotimod, comprises the following steps:
1) L-Glutimic acid 18-20 part, L-4-thiaproline ester 15-17 part are poured in reactor together with ethyl acetate 8-10 part, then add dicyclohexylcarbodiimide 6-8 part and carry out dehydration condensation, fully reaction generates precipitate, filters and removes precipitate, obtained solution, for subsequent use;
2) solution that step 1) is obtained is poured in vessel, adds acetic acid 12-14 part and stir, be then placed in low-temperature evaporation thickener and carry out evaporation process, water content is down to about 50%, obtained concentrated stratified liquid, for subsequent use;
3) by step 2) obtained concentrated stratified liquid carries out extraction process, removal nonaqueous phase liquid, obtained solution, for subsequent use;
4) be poured in vessel by the solution that step 3) is obtained, the refrigerator and cooled being then placed in 7 DEG C freezes crystallization, filters and takes out crystallization, then carry out drying and pulverization process, obtained pidotimod powder, for subsequent use;
5) be poured in blender together with pidotimod powder anhydrous citric acid 4-8 part, stevioside 2-4 part, crospolyvinylpyrrolidone 1-3 part, sodium bicarbonate 2-4 part, carboxymethyl starch sodium 3-5 part, potato starch 6-8 part, L-arginine 2-4 part, tetramisole 1-3 part, Rhizoma amorphophalli glucomannan 4-6 part and step 4) obtained and carry out stir process 30 minutes, obtained mixed-powder, for subsequent use;
6) mixed-powder that step 5) obtains is poured in Highspeedrotarytabletpress the circle being pressed into diameter 6mm, obtained tablet, for subsequent use;
7) gelatin 1-3 part is poured in vessel is then placed in baking oven heating and makes it dissolve, obtained liquid gelatin, for subsequent use;
8) liquid gelatin step 7) obtained is coated onto on the obtained tablet of step 6) uniformly, gets product.
The invention has the beneficial effects as follows: can imbibition by being added with potato starch, carboxymethyl starch sodium and Rhizoma amorphophalli glucomannan, coordinate crospolyvinylpyrrolidone can the rapid disintegrate of medicine, add and be added with sodium bicarbonate and anhydrous citric acid ionizes under the effect of water, and there is metathesis reaction, produce great amount of carbon dioxide, the medicine of disintegrate is melted rapidly, better dispersion medicine.
Detailed description of the invention
Embodiment 1:
A kind of instant pidotimod, comprises the raw material of following parts by weight proportioning: anhydrous citric acid 8 parts, stevioside 2 parts, crospolyvinylpyrrolidone 1 part, sodium bicarbonate 2 parts, carboxymethyl starch sodium 3 parts, potato starch 6 parts, L-Glutimic acid 18 parts, L-4-thiaproline ester 15 parts, ethyl acetate 8 parts, acetic acid 12 parts, dicyclohexylcarbodiimide 6 parts, L-arginine 2 parts, tetramisole 1 part, Rhizoma amorphophalli glucomannan 4 parts and 1 part, gelatin.
A kind of preparation technology of instant pidotimod comprises the following steps:
1) L-Glutimic acid 18-20 part, L-4-thiaproline ester 15-17 part are poured in reactor together with ethyl acetate 8-10 part, then add dicyclohexylcarbodiimide 6-8 part and carry out dehydration condensation, fully reaction generates precipitate, filters and removes precipitate, obtained solution, for subsequent use;
2) solution that step 1) is obtained is poured in vessel, adds acetic acid 12-14 part and stir, be then placed in low-temperature evaporation thickener and carry out evaporation process, water content is down to about 50%, obtained concentrated stratified liquid, for subsequent use;
3) by step 2) obtained concentrated stratified liquid carries out extraction process, removal nonaqueous phase liquid, obtained solution, for subsequent use;
4) be poured in vessel by the solution that step 3) is obtained, the refrigerator and cooled being then placed in 7 DEG C freezes crystallization, filters and takes out crystallization, then carry out drying and pulverization process, obtained pidotimod powder, for subsequent use;
5) be poured in blender together with pidotimod powder anhydrous citric acid 4-8 part, stevioside 2-4 part, crospolyvinylpyrrolidone 1-3 part, sodium bicarbonate 2-4 part, carboxymethyl starch sodium 3-5 part, potato starch 6-8 part, L-arginine 2-4 part, tetramisole 1-3 part, Rhizoma amorphophalli glucomannan 4-6 part and step 4) obtained and carry out stir process 30 minutes, obtained mixed-powder, for subsequent use;
6) mixed-powder that step 5) obtains is poured in Highspeedrotarytabletpress the circle being pressed into diameter 6mm, obtained tablet, for subsequent use;
7) gelatin 1-3 part is poured in vessel is then placed in baking oven heating and makes it dissolve, obtained liquid gelatin, for subsequent use;
8) liquid gelatin step 7) obtained is coated onto on the obtained tablet of step 6) uniformly, gets product.
Embodiment 2:
A kind of instant pidotimod, comprises the raw material of following parts by weight proportioning: anhydrous citric acid 4 parts, stevioside 4 parts, crospolyvinylpyrrolidone 3 parts, sodium bicarbonate 4 parts, carboxymethyl starch sodium 5 parts, potato starch 8 parts, L-Glutimic acid 20 parts, L-4-thiaproline ester 17 parts, ethyl acetate 10 parts, acetic acid 14 parts, dicyclohexylcarbodiimide 8 parts, L-arginine 4 parts, tetramisole 3 parts, Rhizoma amorphophalli glucomannan 6 parts and 3 parts, gelatin.
A preparation technology for instant pidotimod, comprises the following steps:
1) L-Glutimic acid 18-20 part, L-4-thiaproline ester 15-17 part are poured in reactor together with ethyl acetate 8-10 part, then add dicyclohexylcarbodiimide 6-8 part and carry out dehydration condensation, fully reaction generates precipitate, filters and removes precipitate, obtained solution, for subsequent use;
2) solution that step 1) is obtained is poured in vessel, adds acetic acid 12-14 part and stir, be then placed in low-temperature evaporation thickener and carry out evaporation process, water content is down to about 50%, obtained concentrated stratified liquid, for subsequent use;
3) by step 2) obtained concentrated stratified liquid carries out extraction process, removal nonaqueous phase liquid, obtained solution, for subsequent use;
4) be poured in vessel by the solution that step 3) is obtained, the refrigerator and cooled being then placed in 7 DEG C freezes crystallization, filters and takes out crystallization, then carry out drying and pulverization process, obtained pidotimod powder, for subsequent use;
5) be poured in blender together with pidotimod powder anhydrous citric acid 4-8 part, stevioside 2-4 part, crospolyvinylpyrrolidone 1-3 part, sodium bicarbonate 2-4 part, carboxymethyl starch sodium 3-5 part, potato starch 6-8 part, L-arginine 2-4 part, tetramisole 1-3 part, Rhizoma amorphophalli glucomannan 4-6 part and step 4) obtained and carry out stir process 30 minutes, obtained mixed-powder, for subsequent use;
6) mixed-powder that step 5) obtains is poured in Highspeedrotarytabletpress the circle being pressed into diameter 6mm, obtained tablet, for subsequent use;
7) gelatin 1-3 part is poured in vessel is then placed in baking oven heating and makes it dissolve, obtained liquid gelatin, for subsequent use;
8) liquid gelatin step 7) obtained is coated onto on the obtained tablet of step 6) uniformly, gets product.
Embodiment 3:
A kind of instant pidotimod, comprises the raw material of following parts by weight proportioning: anhydrous citric acid 6 parts, stevioside 3 parts, crospolyvinylpyrrolidone 2 parts, sodium bicarbonate 3 parts, carboxymethyl starch sodium 4 parts, potato starch 7 parts, L-Glutimic acid 19 parts, L-4-thiaproline ester 16 parts, ethyl acetate 9 parts, acetic acid 13 parts, dicyclohexylcarbodiimide 7 parts, L-arginine 3 parts, tetramisole 2 parts, Rhizoma amorphophalli glucomannan 5 parts and 2 parts, gelatin.
A preparation technology for instant pidotimod, comprises the following steps:
1) L-Glutimic acid 18-20 part, L-4-thiaproline ester 15-17 part are poured in reactor together with ethyl acetate 8-10 part, then add dicyclohexylcarbodiimide 6-8 part and carry out dehydration condensation, fully reaction generates precipitate, filters and removes precipitate, obtained solution, for subsequent use;
2) solution that step 1) is obtained is poured in vessel, adds acetic acid 12-14 part and stir, be then placed in low-temperature evaporation thickener and carry out evaporation process, water content is down to about 50%, obtained concentrated stratified liquid, for subsequent use;
3) by step 2) obtained concentrated stratified liquid carries out extraction process, removal nonaqueous phase liquid, obtained solution, for subsequent use;
4) be poured in vessel by the solution that step 3) is obtained, the refrigerator and cooled being then placed in 7 DEG C freezes crystallization, filters and takes out crystallization, then carry out drying and pulverization process, obtained pidotimod powder, for subsequent use;
5) be poured in blender together with pidotimod powder anhydrous citric acid 4-8 part, stevioside 2-4 part, crospolyvinylpyrrolidone 1-3 part, sodium bicarbonate 2-4 part, carboxymethyl starch sodium 3-5 part, potato starch 6-8 part, L-arginine 2-4 part, tetramisole 1-3 part, Rhizoma amorphophalli glucomannan 4-6 part and step 4) obtained and carry out stir process 30 minutes, obtained mixed-powder, for subsequent use;
6) mixed-powder that step 5) obtains is poured in Highspeedrotarytabletpress the circle being pressed into diameter 6mm, obtained tablet, for subsequent use;
7) gelatin 1-3 part is poured in vessel is then placed in baking oven heating and makes it dissolve, obtained liquid gelatin, for subsequent use;
8) liquid gelatin step 7) obtained is coated onto on the obtained tablet of step 6) uniformly, gets product.
Experimental example:
Using instant pidotimod of the present invention as experimental group, existing domestic pidotimod as a control group, existing import pidotimod as a control group two, carry out control experiment, concrete outcome is as shown in the table:
Dissolution velocity is compared in instant pidotimod of the present invention and import on the market with domestic pidotimod fast, and dissolubility is high.
The invention has the beneficial effects as follows: can imbibition by being added with potato starch, carboxymethyl starch sodium and Rhizoma amorphophalli glucomannan, coordinate crospolyvinylpyrrolidone can the rapid disintegrate of medicine, add and be added with sodium bicarbonate and anhydrous citric acid ionizes under the effect of water, and there is metathesis reaction, produce great amount of carbon dioxide, the medicine of disintegrate is melted rapidly, better dispersion medicine.
Typical case:
Week certain, middle school student, because school work busy week almost all has a meal in school dining room every day, a period of time there is pharyngalgia in the Later Zhou Dynasty, one of the Five Dynasties, the ability of body resistance disease also starts to be deteriorated, the situation of frequent appearance flu, in a physical education, weekend has fallen in a swoon suddenly, certain was sent to hospital and comprehensively checked week, week, certain was testedly found, body's immunity is low, tonsillitis repeated infection, some pidotimods of doctor prescribed give week, and certain is taken, but effect is general, tonsillitis is repeated infection still, but since week, certain has taken instant pidotimod of the present invention, because medicine dispersive property is outstanding, the utilization rate of the property of medicine is improved, final help week, certain cured tonsillitis.
The above, be only the specific embodiment of the present invention, but protection scope of the present invention is not limited thereto, and any change of expecting without creative work or replacement, all should be encompassed in protection scope of the present invention.
Claims (5)
1. an instant pidotimod, it is characterized in that, comprise the raw material of following parts by weight proportioning: anhydrous citric acid 4-8 part, stevioside 2-4 part, crospolyvinylpyrrolidone 1-3 part, sodium bicarbonate 2-4 part, carboxymethyl starch sodium 3-5 part, potato starch 6-8 part, L-Glutimic acid 18-20 part, L-4-thiaproline ester 15-17 part, ethyl acetate 8-10 part, acetic acid 12-14 part, dicyclohexylcarbodiimide 6-8 part, L-arginine 2-4 part, tetramisole 1-3 part, Rhizoma amorphophalli glucomannan 4-6 part and gelatin 1-3 part.
2. a kind of instant pidotimod as claimed in claim 1, it is characterized in that, comprise the raw material of following parts by weight proportioning: anhydrous citric acid 8 parts, stevioside 2 parts, crospolyvinylpyrrolidone 1 part, sodium bicarbonate 2 parts, carboxymethyl starch sodium 3 parts, potato starch 6 parts, L-Glutimic acid 18 parts, L-4-thiaproline ester 15 parts, ethyl acetate 8 parts, acetic acid 12 parts, dicyclohexylcarbodiimide 6 parts, L-arginine 2 parts, tetramisole 1 part, Rhizoma amorphophalli glucomannan 4 parts and 1 part, gelatin.
3. a kind of instant pidotimod as claimed in claim 1, it is characterized in that, comprise the raw material of following parts by weight proportioning: anhydrous citric acid 4 parts, stevioside 4 parts, crospolyvinylpyrrolidone 3 parts, sodium bicarbonate 4 parts, carboxymethyl starch sodium 5 parts, potato starch 8 parts, L-Glutimic acid 20 parts, L-4-thiaproline ester 17 parts, ethyl acetate 10 parts, acetic acid 14 parts, dicyclohexylcarbodiimide 8 parts, L-arginine 4 parts, tetramisole 3 parts, Rhizoma amorphophalli glucomannan 6 parts and 3 parts, gelatin.
4. a kind of instant pidotimod as claimed in claim 1, it is characterized in that, comprise the raw material of following parts by weight proportioning: anhydrous citric acid 6 parts, stevioside 3 parts, crospolyvinylpyrrolidone 2 parts, sodium bicarbonate 3 parts, carboxymethyl starch sodium 4 parts, potato starch 7 parts, L-Glutimic acid 19 parts, L-4-thiaproline ester 16 parts, ethyl acetate 9 parts, acetic acid 13 parts, dicyclohexylcarbodiimide 7 parts, L-arginine 3 parts, tetramisole 2 parts, Rhizoma amorphophalli glucomannan 5 parts and 2 parts, gelatin.
5. a preparation technology for instant pidotimod, is characterized in that, comprises the following steps:
1) L-Glutimic acid 18-20 part, L-4-thiaproline ester 15-17 part are poured in reactor together with ethyl acetate 8-10 part, then add dicyclohexylcarbodiimide 6-8 part and carry out dehydration condensation, fully reaction generates precipitate, filters and removes precipitate, obtained solution, for subsequent use;
2) solution that step 1) is obtained is poured in vessel, adds acetic acid 12-14 part and stir, be then placed in low-temperature evaporation thickener and carry out evaporation process, water content is down to about 50%, obtained concentrated stratified liquid, for subsequent use;
3) by step 2) obtained concentrated stratified liquid carries out extraction process, removal nonaqueous phase liquid, obtained solution, for subsequent use;
4) be poured in vessel by the solution that step 3) is obtained, the refrigerator and cooled being then placed in 7 DEG C freezes crystallization, filters and takes out crystallization, then carry out drying and pulverization process, obtained pidotimod powder, for subsequent use;
5) be poured in blender together with pidotimod powder anhydrous citric acid 4-8 part, stevioside 2-4 part, crospolyvinylpyrrolidone 1-3 part, sodium bicarbonate 2-4 part, carboxymethyl starch sodium 3-5 part, potato starch 6-8 part, L-arginine 2-4 part, tetramisole 1-3 part, Rhizoma amorphophalli glucomannan 4-6 part and step 4) obtained and carry out stir process 30 minutes, obtained mixed-powder, for subsequent use;
6) mixed-powder that step 5) obtains is poured in Highspeedrotarytabletpress the circle being pressed into diameter 6mm, obtained tablet, for subsequent use;
7) gelatin 1-3 part is poured in vessel is then placed in baking oven heating and makes it dissolve, obtained liquid gelatin, for subsequent use;
8) liquid gelatin step 7) obtained is coated onto on the obtained tablet of step 6) uniformly, gets product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510985708.1A CN105497907A (en) | 2015-12-25 | 2015-12-25 | Instant pidotimod and preparation technology thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510985708.1A CN105497907A (en) | 2015-12-25 | 2015-12-25 | Instant pidotimod and preparation technology thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105497907A true CN105497907A (en) | 2016-04-20 |
Family
ID=55706453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510985708.1A Pending CN105497907A (en) | 2015-12-25 | 2015-12-25 | Instant pidotimod and preparation technology thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105497907A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1680427A (en) * | 2005-02-01 | 2005-10-12 | 杨喜鸿 | Water soluble piduomode composite salt and its preparation |
| CN101422445A (en) * | 2007-12-14 | 2009-05-06 | 北京琥珀光华医药科技开发有限公司 | Preparation method and use of pidotimod effervescent tablets |
| CN104447947A (en) * | 2014-11-18 | 2015-03-25 | 成都医路康医学技术服务有限公司 | Process for producing pidotimod |
-
2015
- 2015-12-25 CN CN201510985708.1A patent/CN105497907A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1680427A (en) * | 2005-02-01 | 2005-10-12 | 杨喜鸿 | Water soluble piduomode composite salt and its preparation |
| CN101422445A (en) * | 2007-12-14 | 2009-05-06 | 北京琥珀光华医药科技开发有限公司 | Preparation method and use of pidotimod effervescent tablets |
| CN104447947A (en) * | 2014-11-18 | 2015-03-25 | 成都医路康医学技术服务有限公司 | Process for producing pidotimod |
Non-Patent Citations (2)
| Title |
|---|
| 李慧等: "匹多莫德及其制剂的研究", 《中国药剂学杂志》 * |
| 陈志武等: "《药理学》", 31 January 2013, 河南科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104177545A (en) | Method for preparing super absorbent resin through graft polymerization of hydrogen peroxide-oxidized potato starch | |
| CN102895215A (en) | Cellulose and red alga polysaccharide plant empty capsule and raw material composition and preparation method thereof | |
| CN104687048B (en) | Maca tablet and preparation method thereof | |
| CN102406626A (en) | Pramipexole hydrochloride slow release tablet and preparation method thereof | |
| CN105497907A (en) | Instant pidotimod and preparation technology thereof | |
| CN103623003B (en) | A kind of ZHENZHU MINGMU DIYANYE and preparation method thereof | |
| CN103054828B (en) | Ranitidine bismuth citrate intra-gastric floating sustained-release tablet and preparation method thereof | |
| CN107474117A (en) | A kind of antitumor cyclic peptide and preparation method thereof and medical applications | |
| CN108079022A (en) | A kind of hirudo extract and preparation method and application | |
| CN102743369A (en) | N-acetylcysteine pharmaceutical composition and preparation method thereof | |
| CN103566055B (en) | Callicarpa nudiflora pellet capsule as well as preparation method thereof | |
| CN105496982B (en) | A kind of chitosan tablet and preparation method thereof | |
| CN104523842A (en) | Mulberry leaf powder effervescent tablet and preparation method thereof | |
| CN204183985U (en) | A kind of scratch resistant diaphragm | |
| CN107582539A (en) | Amoxil capsule and preparation method thereof | |
| CN107652382A (en) | A kind of preparation method of flavones purification macroporous absorbent resin | |
| CN109553648A (en) | A kind of preparation of chitosan oligosaccharide and purification process | |
| CN106317203A (en) | Method of extracting and storing high-purity tachyplesin | |
| CN102600476B (en) | Preparation method and application of drug-carrying keratin film | |
| CN105343097A (en) | Composition containing caffeine and application and manufacturing method of composition containing caffeine | |
| CN106265759B (en) | A kind of preparation method of civetta detoxifying pills | |
| Zhengcai et al. | Progress of Chemical Composition and Pharmacological Effects of Meretrix meretrix Linnaeus | |
| CN103054821A (en) | Ibuprofen arginine tablet and preparation method thereof | |
| CN105310989A (en) | Prasugrel oxalate tablet and preparation method of same | |
| CN116082161A (en) | Separation method and application of chlorogenic acid in papaya |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160420 |
|
| RJ01 | Rejection of invention patent application after publication |